This article is a correction to:
Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models
Roberta Lotti1,2*
Jennifer E. Hundt3
Ralf J. Ludwig3
Christoph M. Hammers3
Brydon Bennett2Antonino Amato2
Alessandra Marconi1,2†
Carlo Pincelli1,2†- 1DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy
- 2PinCell s.r.l., Milan, Italy
- 3Lübeck Institute of Experimental Dermatology, University of Lübeck, Lubeck, Germany
A Corrigendum on
Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models
by Lotti R, Hundt JE, Ludwig RJ, Hammers CM, Bennett B, Amato A, Marconi A and Pincelli C (2023) Front. Immunol. 14:1193032. doi: 10.3389/fimmu.2023.1193032
In the published article, there was an error in the author list, and author Christoph M. Hammers was erroneously excluded. The corrected author list appears below.
Roberta Lotti1,2, Jennifer E. Hundt3, Ralf J. Ludwig3, Christoph M. Hammers3, Brydon Bennett2, Antonino Amato2, Alessandra Marconi1,2†, Carlo Pincelli1,2†
A correction has been made to Author contributions.
This sentence previously stated:
“RL, BB, JH, AM, and CP contributed to conception and design of the study. RL and JH performed experiments and data collection. JH and RL analysed data. RL performed the statistical analysis. RL, AM, CP, AA, JH and RJL have discussed and interpreted the data. RL and CP wrote the first draft of the manuscript. RJL, BB, AA and AM wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.”
The corrected sentence appears below:
“RL, BB, JH, AM, and CP contributed to conception and design of the study. RL and JH performed experiments and data collection. JH and RL analysed data. CMH provided scFv. RL performed the statistical analysis. RL, AM, CP, AA, JH and RJL have discussed and interpreted the data. RL and CP wrote the first draft of the manuscript. RJL, BB, AA and AM wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.”
The Acknowledgments, which previously stated “We thank Christoph M. Hammers from Lübeck Institute of Experimental Dermatology for providing scFv.”, has also been deleted.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pemphigus, FasL, acantholysis, drug development, ex-vivo model
Citation: Lotti R, Hundt JE, Ludwig RJ, Hammers CM, Bennett B, Amato A, Marconi A and Pincelli C (2024) Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. Front. Immunol. 15:1331003. doi: 10.3389/fimmu.2024.1331003
Received: 31 October 2023; Accepted: 15 January 2024;
Published: 23 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Lotti, Hundt, Ludwig, Hammers, Bennett, Amato, Marconi and Pincelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roberta Lotti, cm9iZXJ0YS5sb3R0aUB1bmltb3JlLml0; ci5sb3R0aUBwaW5jZWxsLml0
†These authors share senior authorship